On May 18, 2018 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, reported that SL-401 will be the subject of three clinical presentations, including an oral presentation on the pivotal BPDCN program (Press release, Stemline Therapeutics, MAY 18, 2018, View Source [SID1234526804]). Updated data from the ongoing Phase 2 trial in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) will also be presented. Presentations will be delivered at the upcoming 23rdCongress of the European Hematology Association (EHA) (Free EHA Whitepaper), to be held from June 14-17, 2018, in Stockholm, Sweden. Abstracts are now available on the EHA (Free EHA Whitepaper) congress website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the presentations are as follows:

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
• Abstract: S116
• Session: Miscellaneous Treatments in AML
• Presenter: Naveen Pemmaraju, MD; MD Anderson Cancer Center
• Oral Presentation: Friday, June 15; 11:45 – 12:00 CEST (5:45 AM – 6:00 AM ET)
• Location: Room A4

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
• Abstract: PF618
• Session: Myeloproliferative neoplasms – Clinical
• Poster Presentation: Friday, June 15; 17:30 – 19:00 CEST (11:30 AM – 1 PM ET)
• Location: Poster Area

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML
• Abstract: PF626
• Session: Myeloproliferative neoplasms – Clinical
• Poster Presentation: Friday, June 15; 17:30 – 19:00 CEST (11:30 AM – 1 PM ET)
• Location: Poster Area
Ivan Bergstein, M.D., Stemline’s Chief Executive Officer, commented, "We are honored to be showcasing, via oral presentation, the results of our SL-401 pivotal trial in BPDCN to a European audience via the EHA (Free EHA Whitepaper) Congress. We believe this selection underscores SL-401’s robust clinical data and increased global awareness of BPDCN, a devastating malignancy of high unmet medical need. In the U.S., we remain on track to complete our rolling Biologics License Application (BLA) submission this quarter. In Europe, we anticipate feedback later this year from the European Medicines Agency (EMA) regarding the timing of a potential regulatory filing in the European Union. In addition, we and our investigators continue to report encouraging signs of clinical activity and safety in indications beyond BPDCN, including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), and we look forward to presenting updated data from these indications at the conference."

Following each presentation at the conference, the data presented will be available on Stemline’s website (www.stemline.com) under the Scientific Presentations tab.

About BPDCN
Please visit the BPDCN disease awareness booth (#4125) at ASCO (Free ASCO Whitepaper) 2018 and www.bpdcninfo.com.